![Curasight: Management remains confident on its strategy as new financing plan is launched](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
Curasight
HC Andersen Capital erhåller ersättning från Curasight för ett Digitalt IR/Synlighets avtal för bolaget. Läs vår disclaimer.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Läs meraSenaste analyserna
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
![Curasight: Management remains confident on its strategy as new financing plan is launched](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
BioStock: Curasights vd kommenterar kapitalanskaffning och milstolpe
BioStock: Curasight CEO comments on capital raise and milestone
Välkommen med i Inderes community!
Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!
FREE account
PREMIUM account
Curasight to present at HC Andersen Capital
Curasight: Notice of Extraordinary General Meeting
Curasight A/S resolves on directed issues and a loan facility
Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer
BioStock: Curasight tar nästa steg i utvecklingen av pipelinen
BioStock: Curasight committed to progressing pipeline
Redeye: Curasight Q1 - Moving forward
Curasight: Interim report Q1 2024
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial
BioStock: Curasight får grönt ljus från EMA för fas II prostatacancerstudie
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients
![Curasight (one-pager): Halving of market implied likelihood of succes looks exaggerated](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/75b7c302-48f4-4317-8fc2-347e9e556a2d.png)
Curasight (one-pager): Halving of market implied likelihood of succes looks exaggerated
Curasight announces change in the Board of Directors
Resolutions of the Annual General Meeting 2024 of Curasight A/S
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)